Novavax saw a 21% decline due to leadership changes and market volatility. Despite recent setbacks, their strong financial performance in 2024, driven by key events like vaccine trials and partnerships, has boosted investor confidence. Visit the detailed financial health report for insights.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing